NCT04066725View on ClinicalTrials.gov

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

July 25, 2019

Primary Completion Date

March 19, 2021

Study Completion Date

March 19, 2021

Conditions
Melanoma (Skin)
Interventions
DRUG

Aspirin 81 mg

Participants will be given ASA 81 mg orally once daily for a total of 60 days

DRUG

Aspirin 325mg

Participants will be given ASA 325 mg orally once daily for a total of 60 days

DRUG

Placebo oral tablet

Participants will be given placebo orally once daily for a total of 60 days

Trial Locations (1)

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT04066725 - Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma | Biotech Hunter | Biotech Hunter